TY - JOUR
T1 - MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells
AU - Sánchez-Cid, Lourdes
AU - Pons, Mònica
AU - Lozano, Juan José
AU - Rubio, Nuria
AU - Guerra-Rebollo, Marta
AU - Soriano, Aroa
AU - Paris-Coderch, Laia
AU - Segura, Miquel F.
AU - Fueyo, Raquel
AU - Arguimbau, Judit
AU - Zodda, Erika
AU - Bermudo, Raquel
AU - Alonso, Immaculada
AU - Caparrós, Xavier
AU - Cascante, Marta
AU - Rafii, Arash
AU - Kang, Yibin
AU - Martínez-Balbás, Marian
AU - Weiss, Stephen J.
AU - Blanco, Jerónimo
AU - Muñoz, Montserrat
AU - Fernández, Pedro L.
AU - Thomson, Timothy M.
N1 - Publisher Copyright:
© Cid et al.
PY - 2017
Y1 - 2017
N2 - MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR- 200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional or distant metastases relative to patients with primary node-negative tumors. Forced expression of miR-200s in MCF10CA1h mammary cells induced an enhanced epithelial program, aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures while promoting orthotopic tumor growth and lung colonization in vivo. MiR-200s also induced the constitutive activation of the PI3K-Akt signaling through downregulation of PTEN, and the enhanced mammosphere growth and ALDH activity induced in MCF10CA1h cells by miR-200s required the activation of this signaling pathway. Interestingly, the morphology of tumors formed in vivo by cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC). Indeed, the epithelial components of MBC samples expressed significantly higher levels of miR-200s than their mesenchymal components and displayed a marker profile compatible with luminal progenitor cells. We propose that microRNAs of the miR-200 family promote traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells.
AB - MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR- 200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional or distant metastases relative to patients with primary node-negative tumors. Forced expression of miR-200s in MCF10CA1h mammary cells induced an enhanced epithelial program, aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures while promoting orthotopic tumor growth and lung colonization in vivo. MiR-200s also induced the constitutive activation of the PI3K-Akt signaling through downregulation of PTEN, and the enhanced mammosphere growth and ALDH activity induced in MCF10CA1h cells by miR-200s required the activation of this signaling pathway. Interestingly, the morphology of tumors formed in vivo by cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC). Indeed, the epithelial components of MBC samples expressed significantly higher levels of miR-200s than their mesenchymal components and displayed a marker profile compatible with luminal progenitor cells. We propose that microRNAs of the miR-200 family promote traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells.
KW - Epithelial reprogramming
KW - Invasive ductal breast cancer
KW - MiR-200
KW - MicroRNAs
KW - Progenitor luminal cells
UR - http://www.scopus.com/inward/record.url?scp=85031001302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031001302&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.20698
DO - 10.18632/oncotarget.20698
M3 - Article
C2 - 29137351
AN - SCOPUS:85031001302
SN - 1949-2553
VL - 8
SP - 83384
EP - 83406
JO - Oncotarget
JF - Oncotarget
IS - 48
ER -